Saitama Daiichi Pharmaceutical Co., Ltd. Company Profile

06:18 EDT 22nd March 2018 | BioPortfolio

Since the founding of our company in 1963, we have steadily advanced in the areas of research and development and production, in the sincere pursuit of people's health. In this quest, we have become an industry leader in the research, development and production of ointments and liquid preparations, working diligently to meet ever-growing expectations. Some of our success stories include the ethical drugs, Miltax and Actosin Ointment as well as the molded cataplasms, Patecs series and Karoyan series.In recent years, there has been a growing interest in Drug Delivery System (DDS), among the domestic and foreign medical industries. We are actively at work in this field of research and development, especially Ttansdermal Therapeutic Systems (TTS, that provide lasting pharmacological effect with less side effects), with steady and specific progress toward practical application. Applying these technologies, we are engaged in commissioned research and development with other companies, both foreign and domestic. In order to serve the aging society of the future, we continue to further strengthen our research and development of drugs to treat and prevent diseases. In addition, our experience in production technology will allow us to make further advances in commissioned production.
Look to Saitama Daiichi Pharmaceutical Co., Ltd. for future progress.


8-1, Minamisakae-cho


Phone: 81-48-752-7151

News Articles [338 Associated News Articles listed on BioPortfolio]

BRIEF—Hitachi and Daiichi Sankyo reach manufacturing accord

Chūō, Tokyo-based pharmaceutical firm Daiichi Sankyo has awarded Hitachi Chemical a contract to manufacture…

Deals this week: Shanghai Shyndec Pharmaceutical, Aprecia Pharmaceuticals, Daiichi Sankyo Company

Shanghai Shyndec Pharmaceutical plans to raise CNY2.03bn ($307.41m) through the private placement of convertible bonds. The bonds have a maturity...Read More... The post Deals this week: Shanghai Shyn...

Daiichi Sankyo and Puma Biotech to assess combination cancer therapy

Japan-based Daiichi Sankyo has entered a preclinical research collaboration with US-based Puma Biotechnology and Memorial Sloan Kettering Cancer Centre (MSK)...Read More... The post Daiichi Sankyo and...

Daiichi Sankyo and Puma Collaborate with Major Cancer Center in HER2-Mutated Cancer

TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a precli...

Daiichi Sankyo, Puma Biotech ink research pact with MSK cancer centre in HER2─mutated cancer

Daiichi Sankyo Company, Limited and Puma Biotechnology have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi

Daiichi Sankyo Walks Away From Partnership With Nektar

Under the original deal, Nektar is obligated to pay Daiichi a $12.5 million termination payment.

Daiichi Sankyo, Glycotope Enter Strategic ADC Alliance

To develop ADC combining Daiichi's ADC technology with Glycotope's investigational TA-MUC1 antibody

BRIEF—Daiichi Sankyo US reorganization means 280 job cuts

Japanese pharma major Daiichi Sankyo says it will reorganize its US commercial organization as it continues…

Drugs and Medications [285 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Emetrol cherry [WellSpring Pharmaceutical Corporation]


Cetirizine hydrochloride [Pharmaceutical Associates, Inc.]

Cetirizine Hydrochloride Syrup

Giltuss total release [Gil Pharmaceutical Corp]

Drug Facts

PubMed Articles [439 Associated PubMed Articles listed on BioPortfolio]

Assessment of medium-term cardiovascular disease risk after Japan's 2011 Fukushima Daiichi nuclear accident: a retrospective analysis.

To assess the medium-term indirect impact of the 2011 Fukushima Daiichi nuclear accident on cardiovascular disease (CVD) risks and to identify whether risk factors for CVD changed after the accident.

Roles of children and their parents in the reduction of radiation risk after the 2011 Fukushima Daiichi Nuclear Power Plant accident.

On March 11, 2011, Japan experienced its largest recorded earthquake with a magnitude of 9.0. The resulting tsunami caused massive damage to the Fukushima Daiichi Nuclear Power Plant reactors, and the...

Radiocesium contamination in house dust within evacuation areas close to the Fukushima Daiichi nuclear power plant.

Outdoor decontamination efforts have been ongoing since the Fukushima Daiichi nuclear power plant (FDNPP) accident; however, little is known about indoor contamination. Therefore, house dust was sampl...

Pharmaceutical care for patients of the third age in pharmacy organizations as a significant aspect of social gerontology.

There are questions in the article that study mutual relations of patients of elderly and senile age with pharmaceutical experts. It was revealed that pharmacy organizations are an important element i...

Pharmaceutical cocrystals as an opportunity to modify drug properties: From the idea to application. A review.

The properties of many drugs which have been available on the pharmaceutical market for a long time still need to be improved. Cocrystals are the solid state drug modification which can improve such p...

Clinical Trials [296 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to th...

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. ...

Companies [1037 Associated Companies listed on BioPortfolio]

Saitama Daiichi Pharmaceutical Co., Ltd.

Since the founding of our company in 1963, we have steadily advanced in the areas of research and development and production, in the sincere pursuit of people's health. In this quest, we have become a...


DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Fine Chemical Co., Ltd

Daiichi Fine Chemical Co., Ltd. united the fine chemical business of Daiichi Pharmaceutical Group in October 2001.In the economic and social environment in which changes are expected to accelerate in ...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

More Information about "Saitama Daiichi Pharmaceutical Co., Ltd." on BioPortfolio

We have published hundreds of Saitama Daiichi Pharmaceutical Co., Ltd. news stories on BioPortfolio along with dozens of Saitama Daiichi Pharmaceutical Co., Ltd. Clinical Trials and PubMed Articles about Saitama Daiichi Pharmaceutical Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Saitama Daiichi Pharmaceutical Co., Ltd. Companies in our database. You can also find out about relevant Saitama Daiichi Pharmaceutical Co., Ltd. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record